Orphan drug policy analysis in China
Rare diseases have various types, low incidence rates, complex conditions, and are often difficult to diagnose. Due to China's large population, there is a significant number of rare disease patients, but there is a shortage of orphan drugs. Consequently, these patients often find themselves in...
Saved in:
Main Authors: | Meilin Liu (Author), Yanqin Lu (Author), Junfeng Li (Author), Yongtao Zhang (Author), Shanshan Zhang (Author), Yisheng Liu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Orphan Care in China
by: Liu Meng, et al.
Published: (2009) -
Expenditure trends of orphan drugs in Serbia: 8-Year analysis of orphan drug market in Serbia
by: Pejčić Ana V., et al.
Published: (2016) -
Negotiating Medical Insurance Drug Prices: The Role in Reducing Costs of Orphan Drugs for Rare Diseases
by: Jinmiao Lu, et al.
Published: (2023) -
Long way to go: Progress of orphan drug accessibility in China from 2017 to 2022
by: Jia Liu, et al.
Published: (2023) -
Editorial: Orphan GPCRs as emerging drug targets
by: Ye eFang, et al.
Published: (2015)